P14.09 BORTEM-17: A Phase IB/II Single-Arm, Control Non-Randomized, Multicentre, Open Label Clinical Trial for Recurrent Glioblastoma with unmethylated MGMT promoter (NCT03643549)

BACKGROUND: Glioblastoma (GBM) is the most malignant primary brain tumor in adults where median survival in unselected patients is approximately 10 months. There is no standard treatment for patients who progress on temozolomide and patients are best treated within investigational clinical protocols...

Descripción completa

Detalles Bibliográficos
Autores principales: Goplen, D, Rahman, M A, Arnesen, V S, Brekke, J, Simonsen, A, Andreas, W, Marienhagen, K, Oltedal, L, Haasz, J, Miletic, H, Solheim, T S, Brandal, P, Lie, S A, Chekenya, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427365/
http://dx.doi.org/10.1093/neuonc/noab180.135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427365/
http://dx.doi.org/10.1093/neuonc/noab180.135

Ejemplares similares